Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development

“An important role for the American Society for Gene and Cell Therapy to play is to be an advocate for different areas, and regulation is one of those [areas]. We've, for many years had a very close and good relationship with the FDA... ASGCT plays, I think, an important role in bringing people together with the FDA, educating our community about what needs to be done, what's out there, and in and the FDA is now in a position, I think they're going to be approving a lot more therapies, there's so many things in the pipeline, they're getting close to approval, I think the next year or two are just going to be fantastic.

The American Society of Gene and Cell Therapy (ASGCT) held its 27th Annual Meeting on May 7-11, in Baltimore, Maryland. The meeting, the society’s biggest to date, brought together over 8000 researchers, clinicians, academic centers, regulatory agencies, and industry involved in gene and cell therapy work to share their work and generate collaborative discussions in the field.

CGTLive® spoke with Jeffrey Chamberlain, PhD, Professor, Neurology and Medical Genetics, and Adjunct Professor, Biochemistry, and McCaw Endowed Chair, Muscular Dystrophy, University of Washington, who served as ASGCT’s president for 2023-2024, to learn more about ongoing and future research in the fields of cell and gene therapy, Chamberlain stressed that cost is a huge issue to tackle in the field and will hopefully trend downward as economies of scale come into place. He also noted that the ASGCT plays an important role in bringing together regulators with key players in the field.

Click here to register for the 2024 Annual ASGCT Meeting.